Overview
- Dr Reddy’s, which gave an oral undertaking Wednesday, agreed not to make or release semaglutide under the Olymviq name until March 27.
- Novo Nordisk sued in the Delhi High Court, saying Olymviq infringes its Ozempic trademark and arguing that drug names must avoid even a chance of confusion.
- Justice Jyoti Singh said Olymviq sounds phonetically similar to Ozempic and warned that an interim injunction could follow at Friday’s hearing.
- DRL can keep selling its semaglutide under the other brand names Obeda and Mashlo, and the court suggested using Obeda to reduce confusion.
- The dispute follows Novo Nordisk’s Indian semaglutide patent expiry on March 20, which opened the market to fast‑arriving, lower‑cost generics.